US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-21 21:52:48 Source:businessViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:FDIC chairman Martin Gruenberg to step down, White House says
Next:Auburn running back Brian Battie on ventilator after weekend shooting in Florida, coach says
You may also like
- OpenAI pauses ChatGPT voice after Scarlett Johansson comparisons
- NOT REAL NEWS: A look at what didn't happen this week
- What to expect in Indiana's presidential and state primaries
- Black trainer Larry Demeritte brings his $11,000 horse to the Kentucky Derby
- Culture festival showcases integration
- Jewish students grapple with how to respond to pro
- Anchovies draw crush of sea lions to San Francisco piers, the most in 15 years
- Denmark to liberalize its abortion law to allow the procedure until 18th week of pregnancy
- Children are evacuated from school 'during an exam' after threat made via email